0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Orphan Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

Orphan Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00 – $ 8,900.00

Orphan Drugs Market: By Disease Type (Oncologic Diseases, Metabolic Diseases, Hematologic and Immunologic Diseases, Infectious Diseases, Neurologic Diseases) Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores) End User and Geography

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category: Tag:
Report

Description

1. Executive Summary
2. Global Orphan Drugs Market Introduction
2.1. Global Orphan Drugs Market – Taxonomy
2.2. Global Orphan Drugs Market –Definitions
2.2.1. Disease Type
2.2.2. Indication
2.2.3. Distribution Channel
2.2.4. End User
3. Global Orphan Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Orphan Drugs Market Dynamic
3.6. Global Orphan Drugs Market – Competition Landscape
3.7. Epidemiology
4. Global Orphan Drugs Market Analysis,2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Orphan Drugs Market, By Disease Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Oncologic Diseases
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Metabolic Diseases
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Hematologic and Immunologic Diseases
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Infectious Diseases
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Neurologic Diseases
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Other Rare Diseases
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Orphan Drugs Market Forecast, By Indication, 2017 – 2021 and Forecast, 2022 – 2028(Revenue, USD Mn)
6.1. Non-Hodgkin Lymphoma
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Acute Myeloid Leukemia
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Cystic Fibrosis
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Glioma
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Pancreatic Cancer
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Ovarian Cancer
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Multiple Myeloma
6.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Duchenne Muscular Dystrophy
6.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Graft vs Host Disease
6.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Renal Cell Carcinoma
6.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Others
6.11.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
7. Global Orphan Drugs Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028(Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Stores
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Orphan Drugs Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel and Region, 2022 – 2028
9. North America Orphan Drugs MarketAnalysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Oncologic Diseases
9.1.2. Metabolic Diseases
9.1.3. Hematologic and Immunologic Diseases
9.1.4. Infectious Diseases
9.1.5. Neurologic Diseases
9.1.6. Other Rare Diseases
9.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Non-Hodgkin Lymphoma
9.2.2. Acute Myeloid Leukemia
9.2.3. Cystic Fibrosis
9.2.4. Glioma
9.2.5. Pancreatic Cancer
9.2.6. Ovarian Cancer
9.2.7. Multiple Myeloma
9.2.8. Duchenne Muscular Dystrophy
9.2.9. Graft vs Host Disease
9.2.10. Renal Cell Carcinoma
9.2.11. Others
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Stores
9.3.4. Others
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
9.6. North America Orphan Drugs Market Dynamics – Trends
10. Europe Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Oncologic Diseases
10.1.2. Metabolic Diseases
10.1.3. Hematologic and Immunologic Diseases
10.1.4. Infectious Diseases
10.1.5. Neurologic Diseases
10.1.6. Other Rare Diseases
10.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Non-Hodgkin Lymphoma
10.2.2. Acute Myeloid Leukemia
10.2.3. Cystic Fibrosis
10.2.4. Glioma
10.2.5. Pancreatic Cancer
10.2.6. Ovarian Cancer
10.2.7. Multiple Myeloma
10.2.8. Duchenne Muscular Dystrophy
10.2.9. Graft vs Host Disease
10.2.10. Renal Cell Carcinoma
10.2.11. Others
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Stores
10.3.4. Others
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
10.6. Europe Orphan Drugs Market Dynamics – Trends
11. Asia-Pacific Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Oncologic Diseases
11.1.2. Metabolic Diseases
11.1.3. Hematologic and Immunologic Diseases
11.1.4. Infectious Diseases
11.1.5. Neurologic Diseases
11.1.6. Other Rare Diseases
11.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Non-Hodgkin Lymphoma
11.2.2. Acute Myeloid Leukemia
11.2.3. Cystic Fibrosis
11.2.4. Glioma
11.2.5. Pancreatic Cancer
11.2.6. Ovarian Cancer
11.2.7. Multiple Myeloma
11.2.8. Duchenne Muscular Dystrophy
11.2.9. Graft vs Host Disease
11.2.10. Renal Cell Carcinoma
11.2.11. Others
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Stores
11.3.4. Others
11.4. Country Analysis2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
11.6. Asia-Pacific Orphan Drugs Market Dynamics – Trends
12. Latin America Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Oncologic Diseases
12.1.2. Metabolic Diseases
12.1.3. Hematologic and Immunologic Diseases
12.1.4. Infectious Diseases
12.1.5. Neurologic Diseases
12.1.6. Other Rare Diseases
12.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Non-Hodgkin Lymphoma
12.2.2. Acute Myeloid Leukemia
12.2.3. Cystic Fibrosis
12.2.4. Glioma
12.2.5. Pancreatic Cancer
12.2.6. Ovarian Cancer
12.2.7. Multiple Myeloma
12.2.8. Duchenne Muscular Dystrophy
12.2.9. Graft vs Host Disease
12.2.10. Renal Cell Carcinoma
12.2.11. Others
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Stores
12.3.4. Others
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
12.6. Latin America Orphan Drugs Market Dynamics – Trends
13. Middle East and Africa Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Oncologic Diseases
13.1.2. Metabolic Diseases
13.1.3. Hematologic and Immunologic Diseases
13.1.4. Infectious Diseases
13.1.5. Neurologic Diseases
13.1.6. Other Rare Diseases
13.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Non-Hodgkin Lymphoma
13.2.2. Acute Myeloid Leukemia
13.2.3. Cystic Fibrosis
13.2.4. Glioma
13.2.5. Pancreatic Cancer
13.2.6. Ovarian Cancer
13.2.7. Multiple Myeloma
13.2.8. Duchenne Muscular Dystrophy
13.2.9. Graft vs Host Disease
13.2.10. Renal Cell Carcinoma
13.2.11. Others
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Stores
13.3.4. Others
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
13.6. MEA Orphan Drugs Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Astrazeneca Plc
14.2.2. AOP Orphan Pharmaceuticals GmbH
14.2.3. Eli Lilly And Co.
14.2.4. F. Hoffmann-La Roche Ltd.
14.2.5. Gilead Sciences Inc.
14.2.6. Johnson & Johnson
14.2.7. Merck & Co.
14.2.8. Novartis Ag
14.2.9. Pfizer Inc.
14.2.10. Sanofi-Aventis
14.2.11. Takeda Pharmaceutical Co., Ltd.
14.2.12. Teva Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Report

Company Profile

  • Astrazeneca Plc
  • AOP Orphan Pharmaceuticals GmbH
  • Eli Lilly And Co.
  • Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Merck & Co.
  • Novartis Ag
  • Pfizer Inc.
  • Sanofi-Aventis
  • Teva Pharmaceutical Industries Ltd.

Description

1. Executive Summary
2. Global Orphan Drugs Market Introduction
2.1. Global Orphan Drugs Market – Taxonomy
2.2. Global Orphan Drugs Market –Definitions
2.2.1. Disease Type
2.2.2. Indication
2.2.3. Distribution Channel
2.2.4. End User
3. Global Orphan Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Orphan Drugs Market Dynamic
3.6. Global Orphan Drugs Market – Competition Landscape
3.7. Epidemiology
4. Global Orphan Drugs Market Analysis,2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Orphan Drugs Market, By Disease Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Oncologic Diseases
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Metabolic Diseases
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Hematologic and Immunologic Diseases
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Infectious Diseases
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Neurologic Diseases
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Other Rare Diseases
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Orphan Drugs Market Forecast, By Indication, 2017 – 2021 and Forecast, 2022 – 2028(Revenue, USD Mn)
6.1. Non-Hodgkin Lymphoma
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Acute Myeloid Leukemia
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Cystic Fibrosis
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Glioma
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Pancreatic Cancer
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Ovarian Cancer
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Multiple Myeloma
6.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Duchenne Muscular Dystrophy
6.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Graft vs Host Disease
6.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Renal Cell Carcinoma
6.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Others
6.11.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
7. Global Orphan Drugs Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028(Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Stores
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Orphan Drugs Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel and Region, 2022 – 2028
9. North America Orphan Drugs MarketAnalysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Oncologic Diseases
9.1.2. Metabolic Diseases
9.1.3. Hematologic and Immunologic Diseases
9.1.4. Infectious Diseases
9.1.5. Neurologic Diseases
9.1.6. Other Rare Diseases
9.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Non-Hodgkin Lymphoma
9.2.2. Acute Myeloid Leukemia
9.2.3. Cystic Fibrosis
9.2.4. Glioma
9.2.5. Pancreatic Cancer
9.2.6. Ovarian Cancer
9.2.7. Multiple Myeloma
9.2.8. Duchenne Muscular Dystrophy
9.2.9. Graft vs Host Disease
9.2.10. Renal Cell Carcinoma
9.2.11. Others
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Stores
9.3.4. Others
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
9.6. North America Orphan Drugs Market Dynamics – Trends
10. Europe Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Oncologic Diseases
10.1.2. Metabolic Diseases
10.1.3. Hematologic and Immunologic Diseases
10.1.4. Infectious Diseases
10.1.5. Neurologic Diseases
10.1.6. Other Rare Diseases
10.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Non-Hodgkin Lymphoma
10.2.2. Acute Myeloid Leukemia
10.2.3. Cystic Fibrosis
10.2.4. Glioma
10.2.5. Pancreatic Cancer
10.2.6. Ovarian Cancer
10.2.7. Multiple Myeloma
10.2.8. Duchenne Muscular Dystrophy
10.2.9. Graft vs Host Disease
10.2.10. Renal Cell Carcinoma
10.2.11. Others
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Stores
10.3.4. Others
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
10.6. Europe Orphan Drugs Market Dynamics – Trends
11. Asia-Pacific Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Oncologic Diseases
11.1.2. Metabolic Diseases
11.1.3. Hematologic and Immunologic Diseases
11.1.4. Infectious Diseases
11.1.5. Neurologic Diseases
11.1.6. Other Rare Diseases
11.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Non-Hodgkin Lymphoma
11.2.2. Acute Myeloid Leukemia
11.2.3. Cystic Fibrosis
11.2.4. Glioma
11.2.5. Pancreatic Cancer
11.2.6. Ovarian Cancer
11.2.7. Multiple Myeloma
11.2.8. Duchenne Muscular Dystrophy
11.2.9. Graft vs Host Disease
11.2.10. Renal Cell Carcinoma
11.2.11. Others
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Stores
11.3.4. Others
11.4. Country Analysis2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
11.6. Asia-Pacific Orphan Drugs Market Dynamics – Trends
12. Latin America Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Oncologic Diseases
12.1.2. Metabolic Diseases
12.1.3. Hematologic and Immunologic Diseases
12.1.4. Infectious Diseases
12.1.5. Neurologic Diseases
12.1.6. Other Rare Diseases
12.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Non-Hodgkin Lymphoma
12.2.2. Acute Myeloid Leukemia
12.2.3. Cystic Fibrosis
12.2.4. Glioma
12.2.5. Pancreatic Cancer
12.2.6. Ovarian Cancer
12.2.7. Multiple Myeloma
12.2.8. Duchenne Muscular Dystrophy
12.2.9. Graft vs Host Disease
12.2.10. Renal Cell Carcinoma
12.2.11. Others
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Stores
12.3.4. Others
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
12.6. Latin America Orphan Drugs Market Dynamics – Trends
13. Middle East and Africa Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. By  Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Oncologic Diseases
13.1.2. Metabolic Diseases
13.1.3. Hematologic and Immunologic Diseases
13.1.4. Infectious Diseases
13.1.5. Neurologic Diseases
13.1.6. Other Rare Diseases
13.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Non-Hodgkin Lymphoma
13.2.2. Acute Myeloid Leukemia
13.2.3. Cystic Fibrosis
13.2.4. Glioma
13.2.5. Pancreatic Cancer
13.2.6. Ovarian Cancer
13.2.7. Multiple Myeloma
13.2.8. Duchenne Muscular Dystrophy
13.2.9. Graft vs Host Disease
13.2.10. Renal Cell Carcinoma
13.2.11. Others
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Stores
13.3.4. Others
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Orphan Drugs Market – Opportunity Analysis Index, By  Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028
13.6. MEA Orphan Drugs Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Astrazeneca Plc
14.2.2. AOP Orphan Pharmaceuticals GmbH
14.2.3. Eli Lilly And Co.
14.2.4. F. Hoffmann-La Roche Ltd.
14.2.5. Gilead Sciences Inc.
14.2.6. Johnson & Johnson
14.2.7. Merck & Co.
14.2.8. Novartis Ag
14.2.9. Pfizer Inc.
14.2.10. Sanofi-Aventis
14.2.11. Takeda Pharmaceutical Co., Ltd.
14.2.12. Teva Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms

Reviews

There are no reviews yet.

Be the first to review “Orphan Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+